Characteristics and outcomes of patients with psoriasis treated with apremilast in the real-world in Austria - results the APPRECIATE study.

IF 3.3 3区医学 Q2 PHARMACOLOGY & PHARMACY

Therapeutic Advances in Chronic Disease Pub Date : 2023-01-01 DOI:10.1177/20406223231152785

Constanze Jonak, Isolde Göttfried, Sylvia Perl-Convalexius, Barbara Gruber, Martina Schütz-Bergmayr, Igor Vujic, Wolfgang Weger, Nikolaus Schicher, Lydia Semlin, Margit Hemetsberger, Myriam Cordey, Paul Sator

{"title":"Characteristics and outcomes of patients with psoriasis treated with apremilast in the real-world in Austria - results the APPRECIATE study.","authors":"Constanze Jonak, Isolde Göttfried, Sylvia Perl-Convalexius, Barbara Gruber, Martina Schütz-Bergmayr, Igor Vujic, Wolfgang Weger, Nikolaus Schicher, Lydia Semlin, Margit Hemetsberger, Myriam Cordey, Paul Sator","doi":"10.1177/20406223231152785","DOIUrl":null,"url":null,"abstract":"Background: Apremilast, an oral phosphodiesterase 4 inhibitor, is approved in the European Union for the treatment of moderate-to-severe chronic plaque psoriasis in adult patients refractory or contraindicated to or intolerant of other systemic therapies.Objectives: The APPRECIATE study assessed apremilast use in real-world practice and its clinical value to physicians and patients. APPRECIATE was a multinational, observational, retrospective, cross-sectional study.Methods: Apremilast effectiveness at 6 (±1) months was assessed on the basis of psoriasis severity and health-related quality-of-life scores and treatment satisfaction using physician/patient-reported outcomes, respectively. We report the Austrian cohort of 72 patients.Results: At 6 (±1) months, three-quarters of patients remained on apremilast, while physicians and patients reported treatment benefits across all psoriasis symptoms and manifestations. Of patients, the majority were satisfied with their treatment and achieved treatment goals considered most relevant. Patients' and physicians' perceptions of treatment effectiveness were aligned, and health-related quality-of-life scores indicated an improvement in the majority of patients. Apremilast tolerability was consistent with the known safety profile.Conclusions: Among psoriasis patients receiving apremilast in Austria, improvement in clinical outcomes were observed and satisfaction with apremilast treatment among patients and physicians was high.Registration: ClinicalTrials.gov NCT02740218.","PeriodicalId":22960,"journal":{"name":"Therapeutic Advances in Chronic Disease","volume":"14 ","pages":"20406223231152785"},"PeriodicalIF":3.3000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/4b/b6/10.1177_20406223231152785.PMC9909071.pdf","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Chronic Disease","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/20406223231152785","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 2

Abstract

Background: Apremilast, an oral phosphodiesterase 4 inhibitor, is approved in the European Union for the treatment of moderate-to-severe chronic plaque psoriasis in adult patients refractory or contraindicated to or intolerant of other systemic therapies.

Objectives: The APPRECIATE study assessed apremilast use in real-world practice and its clinical value to physicians and patients. APPRECIATE was a multinational, observational, retrospective, cross-sectional study.

Methods: Apremilast effectiveness at 6 (±1) months was assessed on the basis of psoriasis severity and health-related quality-of-life scores and treatment satisfaction using physician/patient-reported outcomes, respectively. We report the Austrian cohort of 72 patients.

Results: At 6 (±1) months, three-quarters of patients remained on apremilast, while physicians and patients reported treatment benefits across all psoriasis symptoms and manifestations. Of patients, the majority were satisfied with their treatment and achieved treatment goals considered most relevant. Patients' and physicians' perceptions of treatment effectiveness were aligned, and health-related quality-of-life scores indicated an improvement in the majority of patients. Apremilast tolerability was consistent with the known safety profile.

Conclusions: Among psoriasis patients receiving apremilast in Austria, improvement in clinical outcomes were observed and satisfaction with apremilast treatment among patients and physicians was high.

Registration: ClinicalTrials.gov NCT02740218.

Abstract Image

查看原文本刊更多论文

奥地利现实世界中阿普米司特治疗银屑病患者的特点和结果——APPRECIATE研究的结果。

背景:Apremilast是一种口服磷酸二酯酶4抑制剂，在欧盟被批准用于治疗难治性、禁忌症或不耐受其他全身治疗的成人中至重度慢性斑块性银屑病。目的:APPRECIATE研究评估阿普米司特在现实世界中的应用及其对医生和患者的临床价值。APPRECIATE是一项多国、观察性、回顾性、横断面研究。方法:6(±1)个月时，Apremilast的有效性分别根据银屑病严重程度、健康相关生活质量评分和治疗满意度进行评估，并使用医生/患者报告的结果。我们报告了奥地利队列的72例患者。结果:在6(±1)个月时，四分之三的患者继续使用阿普雷米司特，而医生和患者报告了所有牛皮癣症状和表现的治疗益处。在患者中，大多数人对他们的治疗感到满意，并达到了他们认为最相关的治疗目标。患者和医生对治疗效果的看法是一致的，与健康有关的生活质量评分表明大多数患者的生活质量有所改善。阿普拉米司特耐受性与已知的安全性一致。结论:在奥地利接受阿普米司特治疗的银屑病患者中，观察到临床结果的改善，患者和医生对阿普米司特治疗的满意度很高。注册:ClinicalTrials.gov NCT02740218。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Therapeutic Advances in Chronic Disease Medicine-Medicine (miscellaneous)

CiteScore

6.20

自引率

0.00%

发文量

108

审稿时长

12 weeks

期刊介绍： Therapeutic Advances in Chronic Disease publishes the highest quality peer-reviewed research, reviews and scholarly comment in the drug treatment of all chronic diseases. The journal has a strong clinical and pharmacological focus and is aimed at clinicians and researchers involved in the medical treatment of chronic disease, providing a forum in print and online for publishing the highest quality articles in this area.